Amgen Inc.

NasdaqGS:AMGN Voorraadrapport

Marktkapitalisatie: US$177.9b

Amgen Toekomstige groei

Future criteriumcontroles 2/6

Amgen zal naar verwachting groeien in winst en omzet met respectievelijk 8.7% en 2.8% per jaar. De winst per aandeel zal naar verwachting groeien met 8.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 99.6% zijn.

Belangrijke informatie

8.7%

Groei van de winst

8.54%

Groei van de winst per aandeel

Biotechs winstgroei25.4%
Inkomstengroei2.8%
Toekomstig rendement op eigen vermogen99.56%
Dekking van analisten

Good

Laatst bijgewerkt07 May 2026

Recente toekomstige groei-updates

Recent updates

Analyse-update • Apr 28

AMGN: Recent Rally And Trial Uncertainty Will Pressure Future Returns

Amgen's fair value estimate has moved from about $230.89 to $243.49 as analysts factor in a series of higher price targets from firms across the Street, balanced by several neutral initiations. These initiations point to solid fundamentals but mixed views on potential upside from this level.
Nieuwe analyse • Apr 27

Amgen Inc. (AMGN): The Biotech Titan Braces for a MariTide Moment

Amgen Inc. (AMGN) , the global vanguard of innovative biologics and rare disease therapies, enters the final week of April 2026 in a state of high-stakes clinical anticipation.
Analyse-update • Apr 14

AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.
Seeking Alpha • Apr 07

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy

Summary Amgen Inc. is rated a solid Buy, supported by robust revenue growth, pipeline strength, and recent FDA approvals despite looming patent expiries on legacy drugs. Tepezza's successful Phase 3 subcutaneous trial enhances its competitive position in the Thyroid Eye Disease - TED - market, targeting expanded patient access and chronic use. AMGN's 2026 guidance projects $37–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, with a forward P/E of ~17x and a diverse late-stage pipeline. Tepezza may soon face competition from Viridian Therapeutics, Inc.'s veligrotug in TED, which could be approved in June. Viridian also has a subQ TED therapy in Phase 3 studies. While the market has sold VRDN stock on underwhelming clinical data, approvals for both of its assets is not unlikely, helping the company grow its valuation and grow the TED market for itself and AMGN. Read the full article on Seeking Alpha
Analyse-update • Mar 30

AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.
Analyse-update • Mar 16

AMGN: Fair Outlook Balances Patent Expiries With Late Stage Pipeline Potential

The Analyst Price Target for Amgen has been updated from $327.74 to $350.03 as analysts factor in recent price target increases tied to stronger near term commercial execution, added value from key Phase 3 pipeline assets, and a shift toward discounted cash flow based models that emphasize improved margin assumptions and a slightly lower discount rate. Analyst Commentary Recent Street commentary around Amgen reflects a mix of optimism about the current execution and pipeline, alongside ongoing debate about valuation, product risks, and long term earnings durability.
Analyse-update • Mar 02

AMGN: Obesity And Cardiovascular Pipeline Will Drive Future Cash Generation

The analyst price target for Amgen in this narrative has moved to $432. Analysts point to updated DCF assumptions, slightly lower revenue growth and profit margin inputs, and a modestly higher future P/E multiple supported by recent price target increases across the Street and ongoing confidence in the pipeline and guidance.
Analyse-update • Feb 16

AMGN: Long Patent Expiries And Heavier Spending Will Pressure Future Earnings

Analysts have lifted their price targets on Amgen by about $12 to reflect updated views on fair value, profitability, and future P/E assumptions, while also factoring in a higher discount rate and lower projected revenue growth. Analyst Commentary Recent research on Amgen points to a split view, with several firms lifting price targets while others are turning more cautious.
Analyse-artikel • Feb 11

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.52 on 6th of...
Analyse-update • Feb 02

AMGN: Obesity And Cardiovascular Pipeline Will Shape Long-Term Cash Generation

Analysts have nudged their Amgen price targets higher by about $10 to $20, citing a shift toward discounted cash flow analysis, steady execution in legacy products, and increased confidence in the obesity and cardiovascular pipeline. Analyst Commentary Recent research on Amgen highlights a wide range of opinions, but there is a clear cluster of bullish analysts who are leaning into higher price targets and more constructive ratings.
Analyse-artikel • Jan 21

Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year

Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...
Analyse-update • Jan 19

AMGN: Obesity And Cardiovascular Pipeline Will Support Long-Term Upside Potential

Analysts have raised their price targets on Amgen into a higher range, with moves such as BofA's shift to a discounted cash flow approach and UBS's upgraded view on earnings and pipeline potential, even as others highlight upcoming patent expiries and spending needs that temper expectations. Analyst Commentary Recent research on Amgen shows a mix of cautious and constructive views, but the price target moves cluster in a higher range, with several firms now anchoring their models around pipeline contributions and cash flow potential alongside the existing portfolio.
Analyse-artikel • Jan 07

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52

Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...
Analyse-update • Jan 05

AMGN: Patent Expiries And New Drug Launches Will Shape Future Performance

Analysts nudged their fair value estimate for Amgen higher to about $328 per share, up from roughly $323. This reflects slightly firmer revenue expectations and a higher assumed future P/E, balanced against more conservative profit margin assumptions and mixed Street views that highlight both the stability of the core business and uncertainty around patent expiries and new launches.
Analyse-update • Dec 15

AMGN: Margin Expansion And Pipeline Progress Will Drive Long-Term Upside Potential

Analysts have nudged their fair value estimate for Amgen higher to approximately $425 from about $405, reflecting a more constructive view on the company as a defensive large cap biotech with improving margin potential and an innovation pipeline that, while still facing patent expiry and execution risks, is increasingly seen as capable of supporting long term earnings power. Analyst Commentary Recent Street research on Amgen highlights a balanced but gradually improving sentiment backdrop, with a growing cohort of bullish analysts positioning the company as a core large cap biotech holding.
Analyse-update • Nov 30

AMGN: Future Pipeline Progress And Revenue Diversification Will Shape Performance

Amgen's analyst price target has been raised modestly to $322.88, with analysts citing stable revenue, recent guidance increases, and optimism around its pipeline despite ongoing challenges related to patent expiries. Analyst Commentary Recent Street research provides a nuanced view of Amgen’s valuation, outlook, and potential risk factors, with opinions split between those optimistic about its growth trajectory and those concerned about near-term challenges.
Analyse-update • Nov 16

AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance

Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.
Analyse-artikel • Aug 13

Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are

Even though Amgen Inc. ( NASDAQ:AMGN ) posted strong earnings, investors appeared to be underwhelmed. We have done some...
Analyse-artikel • Aug 01

Is Amgen (NASDAQ:AMGN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyse-artikel • Jun 20

Amgen Inc.'s (NASDAQ:AMGN) Earnings Haven't Escaped The Attention Of Investors

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...
Analyse-artikel • May 16

It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year

Key Insights Amgen to hold its Annual General Meeting on 23rd of May Salary of US$1.87m is part of CEO Bob Bradway's...
Seeking Alpha • Apr 17

Amgen: The Biotech That Knows How To Make Money

Summary Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achieved record revenues of $33.4 billion in 2024, with strong EBITDA growth and high free cash flow, despite increased debt from acquisitions. The company's balanced business model and innovative pipeline, including promising drugs in oncology and cardiometabolic diseases, support a "Buy" rating with a 16.44% growth potential. Key risks include expiring patents and regulatory pressures, but Amgen's diversified strategy and strong cash flow position it well for future growth. Read the full article on Seeking Alpha
Nieuwe analyse • Apr 08

Biosimilar Competition And TEPEZZA Approvals Will Define Future Path

Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.
Nieuwe analyse • Apr 08

Expanding Oncology Portfolio And International Launches Will Unlock Potential

Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.
Seeking Alpha • Mar 31

Amgen: Excellent Buy And Hold For A Volatile Market

Summary Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock. Read the full article on Seeking Alpha
Seeking Alpha • Mar 10

Amgen: Riding The MariTide Of Monthly Weight Loss

Summary Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism and less frequent dosing could enhance weight loss and diabetes management, potentially capturing a significant market share. Analysts project MariTide could generate $5 billion in peak annual revenue, bolstering Amgen's growth amidst competition from Eli Lilly, Novo Nordisk, and others. Despite competitive pressures and regulatory risks, MariTide's advancement into Phase 3 trials positions Amgen for mid-to-high single-digit revenue growth, making AMGN stock a "buy". Read the full article on Seeking Alpha
Seeking Alpha • Feb 26

Amgen Stock: Why I Still Rate It A 'Buy'

Summary In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3, Tezspire achieved sales of $296 million in Q4 2024, an increase of 67.2% year-over-year. On the other hand, sales of Repatha, the flagship of Amgen's cardiovascular franchise, reached $606 million, an increase of 45.3% compared to the fourth quarter of 2023. In this article, dear Seeking Alpha readers, you will learn about additional factors that explain why I continue to cover AMGN stock with a 'Buy' rating. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NasdaqGS:AMGN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202839,7059,62814,19914,84427
12/31/202738,7439,10213,87914,18532
12/31/202637,7798,36712,71913,45432
3/31/202637,2207,8008,59710,756N/A
12/31/202536,7517,7118,1009,958N/A
9/30/202535,9717,00511,53913,126N/A
6/30/202534,9176,61910,60512,013N/A
3/31/202534,1265,93310,91512,192N/A
12/31/202433,4244,09010,39411,490N/A
9/30/202432,5344,2306,2837,257N/A
6/30/202430,9343,1305,4816,446N/A
3/31/202429,5323,7637,0988,096N/A
12/31/202328,1906,7177,3598,471N/A
9/30/202326,8337,5669,37910,582N/A
6/30/202326,5827,9799,68510,800N/A
3/31/202326,1907,9177,5318,621N/A
12/31/202226,3236,5528,7859,721N/A
9/30/202226,3306,8358,9979,880N/A
6/30/202226,3846,5768,3559,320N/A
3/31/202226,3165,7238,4179,321N/A
12/31/202125,9795,8938,3819,261N/A
9/30/202125,7675,6097,8408,606N/A
6/30/202125,4845,7468,8979,556N/A
3/31/202125,1647,0859,83510,467N/A
12/31/202025,4247,2649,88910,497N/A
9/30/202024,9877,35210,23510,858N/A
6/30/202024,3017,29910,20910,867N/A
3/31/202023,9667,6758,7959,439N/A
12/31/201923,3627,842N/A9,150N/A
9/30/201923,3958,067N/A9,830N/A
6/30/201923,5627,958N/A9,726N/A
3/31/201923,7508,075N/A10,414N/A
12/31/201823,7478,394N/A11,296N/A
9/30/201823,3192,202N/A11,114N/A
6/30/201823,1882,364N/A11,295N/A
3/31/201822,9392,219N/A11,519N/A
12/31/201722,8491,979N/A11,177N/A
9/30/201723,0128,178N/A11,265N/A
6/30/201723,0508,174N/A10,473N/A
3/31/201722,9287,893N/A10,824N/A
12/31/201622,9917,722N/A10,354N/A
9/30/201622,5627,587N/A9,327N/A
6/30/201622,4747,433N/A9,557N/A
3/31/201622,1567,216N/A10,164N/A
12/31/201521,6626,939N/A9,731N/A
9/30/201521,4576,433N/A10,103N/A
6/30/201520,7655,814N/A9,952N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei AMGN ( 8.7% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van AMGN ( 8.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.7% per jaar).

Hoge groeiwinsten: De winst van AMGN zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van AMGN ( 2.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).

Hoge groei-inkomsten: De omzet van AMGN ( 2.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen AMGN zal naar verwachting over 3 jaar zeer hoog zijn ( 99.6 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/12 22:52
Aandelenkoers aan het einde van de dag2026/05/12 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Amgen Inc. wordt gevolgd door 61 analisten. 32 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
David ToungArgus Research Company
Brian SkorneyBaird
Emily FieldBarclays